Search
Menu
Home
HTB
2001
November
HTB
November 2001
Contents
Conference reports
8th European Conference on Clinical Aspects and Treatment of HIV-infection, Athens, 28-31 October 2001
HIV drug resistance can develop under HAART at low levels of viraemia
Combinations of lopinavir/r and amprenavir in heavily treatment experienced patients
Further reports of benefits of polylactic acid for facial lipoatrophy
GigaHAART study shows benefit of treatment interruption prior to treatment with >7 drugs in highly treatment experienced patients
Tenofovir DF 907 study
The Max Cmin 1 trial: indinavir/ritonavir vs. saquinavir/ritonavir
No significant drug interactions found between tenofovir DF and indinavir, lopinavir/r, lamivudine, or efavirenz
Ritonavir corrects drug interaction between efavirenz and saquinavir
Lopinavir/r effective in naive patients after three years of treatment
Antiretrovirals
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study
European CPMP gives positive opinion for European licensing of tenofovir DF
EC approves abacavir for use by HIV-infected children
Report on salvage therapy from the 39th annual meeting of the IDSA
Side effects
Preventable factors linked to indinavir-associated renal complications
Nerve growth factor improves HIV-associated sensory neuropathy
Lipodystrophy in HAART-treated patients may have multifactorial aetiology
Coinfections and complications
HIV infection may trigger neurologic disorder
Hepatitis coinfection
Daily injection more effective than thrice-weekly interferon alpha-2b for HCV/HIV
Basic science and immunology
HIV infects naive T cells leading to depletion
Rapidly progressive HIV case highlights importance of specific immune response
CCR5 density on T cells directly correlates with HIV disease progression
Human herpes virus 6 prevents CCR5 tropic HIV from spreading in human tissue cultures
Drug resistance
Patients refractory to HIV treatment require close monitoring
Other news
South Africa hits out at pharmaceutical companies on AIDS drugs
On the web
The drug development pipeline
When to start treatment tecommendations
PDFs
Volume 2 Number 9 November 2001 PDF
HTB RSS
Early access
Future PrEP and new results from PURPOSE 1 and 2: does HIV exposure explain incident cases?
21 November 2024
Glasgow HIV Congress 2024
10 November 2024
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
Bipolar disorder in people living with HIV
1 November 2024
All early access reports
Current issues
November 2024
October 2024
September 2024
Back issues
Special report
HTB news: i-Base changes during 2024
1 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate